Five Prime Therapeutics Inc. (NASDAQ:FPRX)’s share price was up 2.9% on Thursday . The stock traded as high as $44.55 and last traded at $43.98, with a volume of 173,659 shares. The stock had previously closed at $42.73.

Several equities analysts recently weighed in on FPRX shares. Zacks Investment Research raised Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Tuesday, April 5th. BMO Capital Markets began coverage on Five Prime Therapeutics in a report on Tuesday, April 12th. They issued a “market perform” rating and a $50.00 price target for the company. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a report on Monday, April 18th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a report on Sunday, May 8th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a report on Sunday, May 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $45.80.

The stock has a 50-day moving average price of $42.47 and a 200 day moving average price of $39.46. The company has a market capitalization of $1.18 billion and a price-to-earnings ratio of 4.94.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.22. During the same quarter in the previous year, the business posted ($0.44) EPS. The business had revenue of $6.50 million for the quarter, compared to the consensus estimate of $5.26 million. The company’s revenue for the quarter was up 51.2% on a year-over-year basis. Equities analysts predict that Five Prime Therapeutics Inc. will post ($2.35) earnings per share for the current year.

In other Five Prime Therapeutics news, Director Franklin M. Berger purchased 5,000 shares of Five Prime Therapeutics stock in a transaction that occurred on Friday, April 22nd. The stock was acquired at an average price of $49.47 per share, for a total transaction of $247,350.00. Following the completion of the acquisition, the director now owns 81,980 shares of the company’s stock, valued at approximately $4,055,550.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Marc Belsky sold 34,102 shares of Five Prime Therapeutics stock in a transaction dated Friday, April 22nd. The stock was sold at an average price of $50.00, for a total value of $1,705,100.00. Following the transaction, the chief financial officer now owns 88,410 shares of the company’s stock, valued at approximately $4,420,500. The disclosure for this sale can be found here.

A number of institutional investors have bought and sold shares of FPRX. ProShare Advisors LLC boosted its position in Five Prime Therapeutics by 16.9% in the fourth quarter. ProShare Advisors LLC now owns 25,418 shares of the company’s stock worth $1,055,000 after buying an additional 3,682 shares during the last quarter. Oxford Asset Management purchased a new stake in shares of Five Prime Therapeutics during the fourth quarter worth about $1,241,000. Russell Frank Co purchased a new stake in shares of Five Prime Therapeutics during the fourth quarter worth about $1,265,000. EAM Investors LLC purchased a new stake in shares of Five Prime Therapeutics during the fourth quarter worth about $1,549,000. Finally, California State Teachers Retirement System boosted its stake in shares of Five Prime Therapeutics by 7.3% in the fourth quarter. California State Teachers Retirement System now owns 42,025 shares of the company’s stock worth $1,744,000 after buying an additional 2,842 shares in the last quarter.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.